Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14407776 | 0.86 | MPO (0.57) | SIGMAR1CXCR4MPOKMT2ATDP1 | |
| SCHEMBL21416735 | 0.83 | LMNA (0.59) | LMNASIGMAR1CXCR4CHRM2CYP1A2 | |
| SCHEMBL30543439 | 0.83 | LMNA (0.51) | LMNASIGMAR1CXCR4CHRM2CYP1A2 | |
| SCHEMBL1641681 | 0.82 | ALDH1A1 (0.58) | LMNASIGMAR1MPOMEN1KMT2A | |
| SCHEMBL21799472 | 0.81 | LMNA (0.62) | LMNASIGMAR1CXCR4MPOCHRM2 | |
| SCHEMBL29922612 | 0.81 | LMNA (0.62) | LMNASIGMAR1CXCR4MPOCHRM2 | |
| SCHEMBL2912056 | 0.81 | ALDH1A1 (0.61) | LMNASIGMAR1MPOMEN1KMT2A | |
| SCHEMBL27535071 | 0.79 | MPO (0.46) | LMNASIGMAR1CXCR4MPOKMT2A | |
| SCHEMBL14407170 | 0.78 | LMNA (0.62) | LMNASIGMAR1CXCR4MPOCHRM2 | |
| SCHEMBL22285518 | 0.78 | LMNA (0.62) | LMNASIGMAR1CXCR4MPOCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025188678-A9 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250288611-A1 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. | 2025-09-18 | — | — | US | disclosed |
| US-20250276018-A1 | CAR CONSTRUCTS AND METHODS OF TREATMENT | AFFYIMMUNE THERAPEUTICS INC (US) | 2025-09-04 | — | — | US | disclosed |
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10966987-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020092650-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-05-07 | — | — | WO | disclosed |
| US-10398703-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-9877970-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-4153794-A | ANTIHISTAMINES, ANTICONVULSANTS, EXPECTORANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-05-08 | — | — | US | disclosed |
| US-4091220-A | RESPIRATORY TRACK FLUID SECRETION STIMULATORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966987-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | LMNA 2026/4885SIGMAR1 1488/4885CXCR4 947/4885 |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | LMNA 2026/4885SIGMAR1 1488/4885CXCR4 947/4885 |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | LMNA 2026/4885SIGMAR1 1488/4885CXCR4 947/4885 |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | LMNA 2026/4885SIGMAR1 1488/4885CXCR4 947/4885 |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | LMNA 2026/4885SIGMAR1 1488/4885CXCR4 947/4885 |
| US-10398703-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | LMNA 2026/4885SIGMAR1 1488/4885CXCR4 947/4885 |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | LMNA 2026/4885SIGMAR1 1488/4885CXCR4 947/4885 |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | CD4, ICOS, NFATC1 | LMNA 3186/4885SIGMAR1 4529/4885CXCR4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.